GLOBAL GENOMICS GROUP LLC has a total of 16 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, EPO (European Patent Office) and Taiwan. Its main competitors in its focus markets measurement and pharmaceuticals are GUANGZHOU JINDIAN JINGFANG PHARMACEUTICAL CO LTD, ATTOQUANT DIAGNOSTICS GMBH and FARBER BORIS.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Taiwan | 2 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Hungary | 1 | |
#7 | Israel | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Mexico | 1 | |
#10 | Singapore | 1 | |
#11 | WIPO (World Intellectual Property Organization) | 1 | |
#12 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Measurement | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Voros Szilard | 13 |
#2 | Brown Bradley O | 13 |
#3 | Marvasty Idean B | 13 |
#4 | Szilard Voros | 2 |
#5 | Bradley O Brown | 2 |
#6 | Idean B Marvasty | 2 |
Publication | Filing date | Title |
---|---|---|
US2019227085A1 | Low density lipoprotein triglycerides (ldl-tg) as a biomarker of cardiovascular disease and uses thereof | |
US2016202239A1 | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease |